LARGE VESSEL INVOLVEMENT IN BEHCET'S DISEASE

F. Shahram^{*}, A. Nadji, AR. Jamshidi and F. Davatchi

Department of Rheumatology, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Abstract- Large vessel involvement is one of the hallmarks of Behcet's disease (BD) but its prevalence varies widely due to ethnic variation or environmental factors. The aim of this study is to find the characteristics of vasculo-Behcet (VB) in Iran. In a cohort of 4769 patients with BD, those with vascular involvement were selected. Different manifestations of disease were compared with the remaining group of patients. A confidence interval at 95% (CI) was calculated for each item. Vascular involvement was seen in 409 cases (8.6%; CI, 0.8). Venous involvement was seen in 396 cases, deep vein thrombosis in 294 (6.2%; CI, 0.7), superficial phlebitis in 108 (2.3%; CI, 0.4) and large vein thrombosis in 45 (0.9%; CI, 0.3). Arterial involvement was seen in 28 patients (25 aneurysms and 4 thromboses). Thirteen patients showed both arterial and venous involvement. The mean age of the patients with VB was slightly higher (P < 0.03), but the disease duration was significantly longer (P<0.0003). VB was more common in men. As the presenting sign, ocular lesions were less frequent in VB (P<0.0006), while skin lesions were over 2 times more common in these cases (P<0.000001). VB was associated with a higher frequency of genital aphthosis, skin involvement, joint manifestations, epididymitis, CNS lesions and GI involvement. The juvenile form was less common in VB (P<0.03). High ESR was more frequent in VB (P=0.000002), but the frequency of false positive VDRL, pathergy phenomenon, HLA-B5 or HLA-B27 showed no significant difference between the two groups. In Iranian patients with BD, vascular involvement is not common and large vessel involvement is rare. It may be sex-related, and is more common in well-established disease with multiple organ involvement and longer disease duration.

Acta Medica Iranica, 42(3): 158-162; 2004

Key words: Behcet's disease, vasculo-Behcet, thrombosis, DVT, phlebitis, aneurysm

INTRODUCTION

Behcet's disease (BD) is a multi-system disease characterized mainly by recurrent oral and genital ulcers, skin and ocular lesions. It spares no organ in the body, and other organs involvement occur as minor manifestations of the disease (1). Vascular involvement, as a hallmark of BD, involves arteries and veins of all sizes (2).

It may be a poor prognostic sign, especially when involving major vessels (3). Like the other manifestations of disease, its prevalence varies

Received: 26 Apr. 2003, Revised: 28 Sep. 2003, Accepted: 15 Oct. 2003

* Corresponding Author:

widely according to reports from different parts of the world (1.8 to 79%) (3-22). The difference may be due to ethnic variation or environmental factors (1). Here we present the prevalence and characteristics of vascular lesions in Iranian patients with BD, and the possible effect of these lesions on disease expression.

MATERIALS AND METHODS

In a cohort of 4769 patients with the diagnosis of BD, registered at our BD unit during the past 27 years (between 1975 and March 2002), those with vascular involvement were selected. The confirmatory diagnostic procedures for venous thrombosis were either doppler sonography or phlebography, and for arterial involvement were

F. Shahram, Department of Rheumatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Tel: +98 21 84902405, Fax: +98 21 8026956 E-mail: shahram@neda.net

either angiography or computerized tomography (CT) scanning. The remaining patients without vascular lesions were assigned as control group (non VB).

A computerized form including 100 clinical and paraclinical parameters was used to register different manifestations of the disease. These data were compared between the two groups by chi square test and corrected by Fisher exact test. Standard deviation for the means (SD), their related standard error of means (SEM), and a confidence interval at 95% (CI) were calculated for each item.

RESULTS

Vascular involvement was seen in 409 cases (8.6%, CI=0.8). The control group included 4360 BD patients. The mean age of the patients was 27 years (SD=9.2, SEM=0.455), slightly higher than the control group (25.9±9.7 years, SEM=0.147) but statistically significant (P<0.03). VB was more common in men (77%±4.1 versus 52%±1.5, P<0.000001), with male/female ratio of 3.4, and the mean disease duration was significantly longer in men (10.4±7.5 versus 9.1±6.9 years, P<0.00003). The mean follow-up time for VB patients was also longer (4.1±4.6 versus 2.8±3.7 years, P<0.00001).

Venous involvement was seen more frequently (396 cases, 8.3%, CI=0.8). They included deep vein thrombosis (DVT) in 294 (6.2%, CI=0.7), superficial phlebitis in 108 (2.3%, CI=0.4), and large vein thrombosis in 45 (0.9%, CI=0.3). In the latter group with large vein thrombosis, the involved vein was superior vena cava in 19 patients, inferior vena cava in 9 and iliofemoral in 10 cases.Brachiocephalic and subclavian veins occlusion were seen each in 1 case. Three patients presented with Budd-Chiari syndrome due to suprahepatic vein occlusion. Two patients presented with portal hypertension, and another one with splenomegaly due to splenic vein thrombosis. We have seen 2 cases of cerebral sinus occlusion and a case of jugular vein thrombosis.

Arterial involvement was seen in 28 patients (0.6%, CI=0.2). Aneurysms were present in 25 patients and thrombosis in 4. In the case of arterial aneurysms, the following arteries were involved: aorta in 9 cases, iliac and femoral artery each in 5

cases, popliteal in 3 cases, posterior tibialis in 2 cases, subclavian, pulmonary and cerebral arteries each in one case. In the 4 cases of arterial thrombosis, the involved arteries were iliac, aorta, and popliteal arteries (2 cases). We encountered 3 cases with pulse weakness, 2 in the radial and 1 in the femoral artery, without any evident arterial thrombosis or aneurysm.

Thirteen patients showed involvement of both arterial and venous systems. The arterial involvement was aneurysmal in all, but thrombosis was also present in 2 of them. The venous involvement was DVT in 8 cases (accompanied by larger vein involvement in 2 cases, and by superficial phlebitis in another one), superficial phlebitis in 5 cases (one with DVT), and large venous involvement in 3 cases (two with DVT). Comparison between the groups with and without vascular involvement showed no significant difference in the presence of positive familial history of BD (4.2%, CI=2.8 versus 5.3%, CI=0.9, P=0.4), or oral aphthosis (47.4%, CI=7.1 versus 50.2%, CI=2.1, P=0.46). But the prevalence of juvenile form of the disease was significantly lower in those with vascular involvement (2.4%, CI=1.5 versus 4.9%, CI=0.6, with P < 0.03). As the presenting sign, ocular lesions were less frequently seen in VB (4.9%, CI=2.1 versus 10.2%, CI=0.9, P<0.0006) and the frequencies of oral and genital aphthosis, and joint manifestations were the same (Table 1). Other manifestations of the disease, notably skin lesions, were over 2 times more common in VB as the first manifestation of the disease (15.9%, CI=3.6 versus 7.4%, CI=0.8, P<0.000001). VB was associated with a higher frequency of genital aphthosis (73.3%, CI=4.3 versus 64.5%, CI=1.4, P<0.0004) and skin involvement (88%, CI=3.1 versus 68.5%, CI=1.4, P < 0.000001). It was very prominent in the case of erythema nodosum (50.6%, CI=4.8 versus 19.6%, CI=1.2, P<0.00001). The frequencies of other major symptoms were nearly the same (Table 2). All the minor manifestations of disease, including joint manifestations (53.8%, CI=4.8 versus 33%, CI=1.4, with P < 0.00001), gastrointestinal involvement (11.7%, CI=3.1 versus 7.5%, CI=0.8, P<0.003), CNS lesions (6.8%, CI=2.5 versus 2.9%, CI=0.5, P < 0.00002), and epididymitis (21%, CI=4.5 versus 9.1%, CI=1.2, P<0.000001) were more frequent in patients with vascular involvement (Table 3).

| Presenting sign | Vascular | Non- | Р |
|-------------------|------------|------------|------------|
| | % (CI) | vascular | value |
| | | % (CI) | |
| Oral aphthosis | 77.8 (4) | 80.6 (1.2) | 0.17 |
| Genital aphthosis | 9.8 (2.9) | 10.4 (0.9) | 0.69 |
| Ocular lesions | 4.9 (2.1) | 10.2 (0.9) | < 0.0006 |
| Joint | 6.8 (2.5) | 5.1 (0.6) | 0.13 |
| manifestations | | | |
| Other involvement | 15.9 (3.6) | 7.4 (0.8) | < 0.000001 |

 Table 1. Comparison between presenting signs of vascular and non-vascular groups

Abbreviation: CI, confidence interval.

In laboratory findings, high ESR was more frequent in VB (65.4%, CI=4.8 versus 52.8%, CI=1.5, with P=0.000002). The frequency of other paraclinical tests such as pathergy phenomenon, urine abnormality, false positive VDRL, HLA-B5 or HLA-B27 showed no significant difference between the two groups (Table 4).

DISCUSSION

Large vessel involvement in BD can take the form of venous thrombosis, arterial occlusions, and arterial aneurysms (2,3,23). Due to their low sensitivity, vascular lesions are not listed among the criteria for diagnosis of BD in most major sets of diagnostic criteria (1,2,23). However they may be distinctive and should suggest the diagnosis of BD when present

 Table 2. Comparison between major manifestations of vascular and non-vascular groups

| Major manifestation | Vascular % (CI) | Non- vascular % (CI) | P value | |
|------------------------|--------------------|----------------------------|------------|--|
| Oral aphthosis | 98.3 (1.4) | 96.5 (0.5) | 0.07 | |
| Genital aphthosis | 73.3 (4.3) | 64.5 (1.4) | < 0.0004 | |
| Skin lesions | 88 (3.1) | 68.5 (1.4) | < 0.000001 | |
| Pseudofolliculitis | 70.9 (4.4) | 60.9 (1.4) | 0.00007 | |
| Erythema | 50.6 (4.8) | 19.6 (1.2) | < 0.000001 | |
| nodosum | | | | |
| Ocular lesions | 51.6 (4.8) | 56.2 (1.5) | 0.07 | |

Abbreviation: CI, confidence interval.

 Table 3. Comparison between minor manifestations of vascular and non-vascular groups

| Minor manifestation | Vascular % (CI) | Non- vascular | P value |
|------------------------|--------------------|------------------|------------|
| | | % (CI) | |
| Joint | 53.8 (4.8) | 33 (1.4) | < 0.000001 |
| manifestations | | | |
| GI involvement | 11.7 (3.1) | 7.5 (0.8) | < 0.003 |
| CNS involvement | 6.8 (2.5) | 2.9 (0.5) | < 0.00002 |
| Epididymitis | 21 (4.5) | 9.1 (1.2) | < 0.000001 |
| (men) | | | |

Abbreviation: CI, confidence interval.

(23).

Among the connective tissue diseases, BD surpasses SLE as a cause of venous occlusive disease (2). According to the literature, the most common vascular lesions are subcutaneous thrombophlebitis and venous occlusion of the upper and lower extremities (3). Thrombosis may be recurrent and may also affect the vena cava, the cerebral venous sinuses and the portal venous system, leading to characteristic clinical syndromes. Although superficial and deep venous thrombosis is associated with a higher risk of thrombosis in other locations as well as arterial lesions (3,23), pulmonary emboli are rare and the role of anticoagulant therapy is uncertain (2).

Arterial involvement includes aneurysm formation (in about two thirds of cases and often multiple), thrombosis, and angiitis of systemic and pulmonary arteries.

 Table 4. Comparison between laboratory findings of vascular and non-vascular groups

| Laboratory finding | Vascular % (CI) | Non- vascular % (CI) | P value |
|-----------------------|--------------------|----------------------------|------------|
| Positive pathergy | 60.8 (4.8) | 57.7 (1.5) | 0.23 |
| test | | | |
| High ESR | 65.4 (4.8) | 52.8 (1.5) | 0.000002 |
| Urine abnormality | 9.6 (3) | 10.9 (1) | 0.42 |
| False positive VDRL | 2.4 (1.6) | 1.6 (0.4) | 0.38 |
| HLA-B5 | 54.3 (5) | 53 (1.5) | 0.62 |
| HLA-B27 | 8 (3) | 9.4 (0.9) | 0.41 |

Abbreviation: CI, confidence interval.

The artery most often affected is the aorta, followed by the pulmonary, femoral, popliteal, subclavian and common carotid arteries. Based on isolated reports, virtually no arteries are spared, including the coronary arteries. Isolated arterial stenoses and occlusions are the least common vascular complications but arterial occlusions are often associated with aneurysms (2).

BD is one of the known acquired disorders that lead to the formation of pulmonary artery aneurysm. These patients can present with asymptomatic abnormalities on chest radiographs, but massive and fatal hemoptysis from ruptured pulmonary artery aneurysms and arteriobronchial fistula may be the unsuspected manifestations of BD. Rupture of these large artery aneurysms is one of the leading causes of death in patients with BD (2). It would be interesting to compare our data with various reports from the other parts of the world (Table 5). In Iranian patients with BD, vascular involvement is not common and large vessel involvement is rare. Similar prevalence is seen in large series, such as Iran and Japan (4), with nationwide surveys. The higher reported frequencies may be in part due to bias of small series or hospital-based selection of the patients, as well as ethnic variations. Vascular lesions were more common in men, and in those with well-established disease, with multiple organ involvement and longer disease duration. The mean time for the emergence of vascular lesions from the time of diagnosis was reported 3.2 years in Turkish patients (3). Recently, we have reported a mean delay time of 6.5 years after the onset of the disease for the appearance of vascular lesions in Iranian patients with BD (24). There is a large difference between our BD patients with and without vascular involvement in different manifesttations of the disease. Higher frequency of genital aphthosis, skin lesions, epididymitis, joint, gastrointestinal, and CNS involvement, as well as high ESR was seen in VB patients (Tables 2 and 3). No relationship seems to exist between vascular involvement and HLA-B5 genetic background, as well as false positive VDRL or pathergy phenomenon in our BD patients (Table 4).

| | Number of patients | Vascular involvement | Venous involvement† | Arterial involvement | Superficial phlebitis |
|--------------------------------------|--------------------|-------------------------|------------------------|-------------------------|--------------------------|
| Iran (Shahram) | 4769 | 8.6 | 7 | 0.6 | 2.3 |
| Japan (Nakae ⁴) | 3316 | 8.9 | | | |
| Korea (Bang ⁵) | 1527 | 1.8 | | | |
| China (Dong Yi ⁶) | 120 | 12.5 | 7.5 | 5 | 2.5 |
| S.Arabia (Al-Dalaan ⁷) | 208 | 33 | 28.4 | 19.2 | |
| Turkey (Sarica ⁸) | 2319 | 14.3 | 6.1 | 0.9 | 9.4 |
| Jordan (Madanat ⁹) | 200 | | 24 | 3.5 | 7 |
| Iraq (Sharqui ¹⁰) | 100 | 21 | 5 | | 16 |
| Israel (Krause ¹¹) | 91 | 26.4 | | | |
| Tunisia (Hamza ¹²) | 515 | 25 | 22 | 4 | |
| Morocco (Benamor ¹³) | 316 | | 21.8 | | |
| Egypt (Assaad Khalil ¹⁴) | 100 | 79 | 55 | 63 | 40 |
| Algeria (Berrah ¹⁵) | 58 | 33 | 30 | 6.9 | 6.9 |
| USA (Calamia ¹⁶) | 164 | 19 | 16.5 | 4.3 | |
| Portugal (de Jesus ¹⁷) | 43 | 28 | 9.3 | 4.7 | 16.3 |
| Italy (Valesini ¹⁸) | 155 | 25.1 | 23.2 | 1.9 | |
| Russia (Prokaeva ¹⁹) | 77 | 18 | 17 | 2.4 | 1.3 |
| Germany (Zouboulis ²⁰) | 141 | 25 | | | 15 |
| England (Chamberlain ²¹) | 32 | | 25 | 3.1 | |
| Greece (Kaklamani ²²) | 101 | 11 | | | |

Table 5. Frequency of vascular involvement in different parts of the world*

*Data are presented as percentage unless otherwise indicated.

†Including deep vein thrombosis and large vein thrombosis.

REFERENCES

1. Davatchi F. Behcet's disease. In: Howe HS, Feng PH, editors. Textbook of Clinical Rheumatology. Singapore: National Arthritis Foundation; 1998. p. 298-315.

2. Lie JT. Vascular involvement in Behcet's disease: arterial and venous and vessels of all sizes. J Rheumatol. 1992; 19(3): 341-343.

3. Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci F, Akkaya S. Vascular involvement in Behcet's disease. J Rheumatol. 1992; 19(3): 402-410.

4. Nakae K, Masaki F, Hashimoto T, Inaba G, Moshizuki M, Sakane T. Recent epidemiological features of Behcet's disease in Japan. In: Wechsler B, Godeau P, editors. Behcet's Disease. Amsterdam: Excerpta Medica; 1993.p. 145-151.

5. Bang D, Lee JH, Lee E-S, et al. Epidemiologic and clinical survey of Behcet's disease in Korea: The first multicenter study. In: Bang D, Lee E, Lee S, editors. Behcet's Disease. Seoul: Design Mecca Publishing CO.; 2000. p. 555-558.

6. Dong Y, Liu J. Vasculo-Behcet's disease. In: Wechsler B, Godeau P, editors. Behcet's Disease. Amsterdam: Excerpta Medica; 1993.p. 527-530.

7. Al-Dalaan A, Al-Shaikh A, Al-Saleh S, Al-Ballaa S. Vascular manifestations of Behcet's disease, Saudi Arabia experience. In: Bang D, Lee E, Lee S, editors. Behcet's Disease. Seoul: Design Mecca Publishing CO.; 2000. p. 312.

8. Sarica R, Akdag Kose A, Kayabali M, Disci R, Erzengin D, Azizlerli G. Vascular involvement in Behcet's disease. In: 10th International Conference on Behcet's disease, June 2002, Berlin, Germany. Programme and abstracts: p 80 (Abstract 096).

9. Madanat W, Fayyad F, Verity D, Zureikat H. Influence of sex on Behcet's disease in Jordan. In: Bang D, Lee E, Lee S, editors. Behcet's Disease. Seoul: Design Mecca Publishing CO.; 2000. p. 90-93.

10. Sharqui K, Al-Araji A, Al-Rawi Z, Al-Yaqubi O, Hatem A. Behcet's disease in Iraqi patients. A prospective study from a newly established multidiscipline Behcet's disease clinic. In: Bang D, Lee E, Lee S, editors. Behcet's Disease. Seoul: Design Mecca Publishing CO.; 2000. p. 60-63.

11. Krause I, Mader R, Sulkes J, et al. The expression of Behcet's disease in Israeli ethnic groups. In: Bang D, Lee E, Lee S, editors. Behcet's Disease. Seoul: Design Mecca Publishing CO.; 2000. p. 73-76.

12. Hamza M. Angio Behcet. In: Wechsler B, Godeau P, editors. Behcet's Disease. Amsterdam: Excerpta Medica; 1993.p. 523-526.

13. Benamor S, Zeroual B, Bennis R, Amraoui A, Bettal S. Maladie de Behcet. 316 cas: Press Med 1990; 19: 1485-1489.

14. Assaad-Khalil S, Rafla S, Yacout Y, et al. Prevalence of cardiovascular involvement in patients with Behcet's disease using angiography, color duplex sonography, doppler echocardiography and CATS. In: Bang D, Lee E, Lee S, editors. Behcet's Disease. Seoul: Design Mecca Publishing CO.; 2000. p. 791-799.

15. Berrah A, Remache A, Ouadahi N, et al. Clinical manifestations of Behcet's disease: analysis of 58 cases. In: Bang D, Lee E, Lee S, editors. Behcet's Disease. Seoul: Design Mecca Publishing CO.; 2000. p. 77-82.

16. Calamia K, Mazlumzadeh M, Balabanova M, Bagheri M, O'Duffy J. Clinical characteristics of United States patients with Behcet's disease. In: Bang D, Lee E, Lee S, editors. Behcet's Disease. Seoul: Design Mecca Publishing CO.; 2000. p. 48-51.

17. de Jesus H, Rosa M, da Costa T, Queiroz M. Vascular involvement in Behcet's disease. An analysis of twelve cases.In: Hamza M, editor. Behcet's Disease. Tunisia: PUB ADHOUA; 1997. p. 303-304.

18. Valesini G, Pivetti Pezzi P, Catarinelli G, Accorinti M, Priori R. Clinical manifestations of Behcet's disease in Italy: Study of 155 patients at Rome University. In: O'Duffy JD, Kokmen E, editors. Behcet's Disease Basic and Clinical Aspects. New York: Marcel Decker Inc; 1991.p. 279-289.

 Prokaeva T, Alekberova Z, Madanat W, Jazdovskiy V, Ermakova N. Behcet's disease in Russia. In: Hamza M, editor. Behcet's Disease. Tunisia: PUB ADHOUA; 1997. p. 190-195.

20. Zouboulis C, Djawari D, Kirch W, et al. Adamantiades-Behcet's diseae in Germany, Data of the German registry in 1996. In: Hamza M, editor. Behcet's Disease. Tunisia: PUB ADHOUA; 1997. p. 180-185.

21. Chamberlain MA. Behcet's syndrome in 32 patients in Yorkshire. Ann Rheum Dis. 1977; 36(6): 491-499.

22. Kaklamani V, Markomichelakis N, Vaiopoulos G, Papazoglou S, Kaklamanis P. Clinical features of Adamantiades-Behcet's disease in greece. In: Bang D, Lee E, Lee S, editors. Behcet's Disease. Seoul: Design Mecca Publishing CO.; 2000. p. 56-59.

23. Schirmer M, Calamia KT, O'Duffy JD. Is there a place for large vessel disease in the diagnostic criteria of Behcet's diseas. J Rheumatol. 1999; 26(12): 2511-2512.

24. Shahram F, Assadi K, Davatchi F, et al. Chronology of clinical manifestations in Behcet's disease, analysis of 3542 cases. In: 10th International Conference on Behcet's disease, June 2002, Berlin, Germany. Programme and abstracts: p 58 (Abstract 006).